Drug Trial Radar · NCT03938792
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Mar 9, 2020
Primary completion
Apr 29, 2025
Study completion Apr 29, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
Conditions
- Hemophilia A
- Hemophilia B
Interventions
PF-06741086Drug
300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
- Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
- Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
- Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
- Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
- Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
- Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
- Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
Locations
62 sites in 20 countries. Site status is shown where the registry gives one.
USF Health Morsani Center For Advanced Healthcare
Tampa, Florida
University of Iowa
Iowa City, Iowa
Northwell Health HTC
New Hyde Park, New York
Washington Institute for Coagulation
Seattle, Washington
National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
Sofia, Bulgaria
UMHAT "Prof.Dr. Stoyan Kirkovich"
Stara Zagora, Bulgaria
McMaster University Medical Centre - Hamilton Health Sciences
Hamilton, Ontario, Canada
McMaster Children's Hospital
Hamilton, Ontario, Canada
McMaster University
Hamilton, Ontario, Canada
The Hospital For Sick Children
Toronto, Ontario, Canada
Beijing Children's Hospital, Capital Medical University
Beijing, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
Hôpital Necker Enfants Malades
Paris, France
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Nirmal Hospital Pvt, Ltd
Surat, Gujarat, India
Sahyadri Clinical Research and Development Center
Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
Christian Medical College
Vellore, Tamil Nadu, India
Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
Perugia, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Milan, Italy
Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
Roma, RM, Italy
Hiroshima University Hospital
Hiroshima, Japan
Nagoya University Hospital - Transfusion Medicine
Nagoya, Aichi-ken, Japan
Sapporo Tokushukai Hospital
Sapporo, Hokkaido, Japan
Saitama Medical University Hospital
Iruma-gun, Saitama, Japan
Hospital Universitario "Dr Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
Mérida, Yucatán, Mexico
Sultan Qaboos University Hospital
Muscat, Oman
FGBOU VO "Samara State Medical University" of MoH of Russia
Samara, Russia
King Abdulaziz University Hospital
Jeddah, Saudi Arabia
King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia
Clinical Center of Serbia
Belgrade, Serbia
Institute for Mother and Child healthcare "Dr Vukan Cupic"
Belgrade, Serbia
Clinical Center Kragujevac
Kragujevac, Serbia
Clinical Center Nis
Niš, Serbia
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.